Frazier said Merck will soon start midstage patient testing of an Alzheimer's disease drug. It works by blocking formation of brain plaques believed to be the underlying cause of the memory-robbing disease. Rival experimental drugs that have had disappointing results recently work differently.
Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.